The leading healthcare company LumenXT Inc. has recently named Marc Beer as its new Chairman of the Board. Marc will bring over two decades of experience to the company. For over twenty years, Marc has been involved in the development and commercialization of biotechnology, pharmaceuticals, medical devices and diagnostics products. Over the course of his career, Beer has been able to demonstrate valuable leadership skills in helping a number of organizations in the healthcare and biotechnology industry succeed.
In a recent statement, Marc Beer said that he is proud to be working with a very dedicated and accomplished group of medical professionals including surgeons. He is also thrilled to be working with a number of leading engineers who have been involved in the advancement of surgical illumination. Marc has said that LumeNXT is a leading company of developing technology that allows surgeons to perform successful surgery more safely. Marc has also said that he believes that LumeNXT has a platform that will likely increase as more surgeries are done with a less invasive approach.
The co founder of LumeNXT Paul Rhyne also made a statement about Marc Beer. He said that Marc has demonstrated a high level of success in a number of different startup companies as he has helped guide them through multiple phases of growth. Ryhne also said that Marc’s vast amount of experience in both starting and guiding companies to profitability and global success will prove to be valuable for LumeNXT.
Marc Beer is the founder, Chairman and Chief Executive Officer of Renovia Inc. He founded the company with the mission to discover and provide the first line of digital therapeutic devices for women. These technology products were intended to help treat women who have disorders of the pelvic floor. Beer founded this company in August of 2016. Before starting up Renovia, Marc Beer served as both the Founding Chairman of Minerva Neurosciences Inc. This company was a clinical stage biopharmaceutical company that focused on developing product candidates for the treatment of central nervous system diseases. Minerva conducted a number of late stage clinical trials as well as therapeutic compounds for various psychological conditions such as schizophrenia. It has also developed treatments for other conditions such as mood disorders, major depression and Parkinson’s disease.
Throughout his career, Paul held a number of key leadership positions at various companies. He was responsible for the commercial launch of various products that treated diseases all over the world. Marc has also helped many biopharmaceutical companies establish growth, issue initial public offerings and completing acquisitions. During his career, Marc Beer has held positions such as the Founder and Chief Executive Officer of Aegerion Pharmaceuticals and the Chairman of the Board of Good Start Genetics Inc. Learn more: https://www.crunchbase.com/person/marc-beer